STAT+: Pharmalittle: We’re reading about Moderna’s flu shot, a death in a gene-editing trial in China, and more

In today's Pharmalittle newsletter: Moderna's mRNA flu shot approved, a death reported in a gene-editing trial in China, and more.

The vaccine relies on the same mRNA technology used in the pharmaceutical company's Covid-19 vaccine

[UN News] Results may be months away, but efforts are advancing towards enhanced treatment and the world's first vaccine for the Bundibugyo species of Ebola, the World Health Organization (WHO) said on Tuesday as deaths and cases rise in the largest ever outbreak on record in the Democratic Republic of the Congo (DRC).

The vaccine relies on the same mRNA technology used in Moderna’s Covid-19 vaccine.

Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and currently has no approved vaccine.

Trial will run at three sites in Canada and aims to enroll about 80 healthy adults